All News

In this interview, Dr. David Albala sits down to discuss his award-winning poster on live-cell phenotypic biomarkers at the 2016 AUA with Urology Times Editorial Consultant, Dr. J. Brantley Thrasher.

Given the advancement in both pathophysiology and precision-guided approaches for prostate cancer, we assembled a panel of expert urologists to discuss clinically important aspects of ADT that will assist busy clinician decision makers in their optimization of outcomes for their advanced prostate cancer population.

Jamin Brahmbhatt, MD, discusses his favorite tools to efficiently maintain an active online presence.

Facing uncertainty in Medicare and increasing regulatory and insurer burdens, the leaders of organizations representing urologists across the country gathered in mid-August for the 9th Annual AACU State Society Network Advocacy Conference.

Urologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.

The authors of a recent research letter reported a 6% drop in incidence rates for early-stage prostate cancer in men 50 years of age and older from 2012 to 2013.

A recent study suggests that a man’s race/ethnicity might influence decisions about undergoing treatment and re-biopsies.

Here are simple, often inexpensive ways in which urologists can reclaim their engagement and passion for practicing medicine.

The American Medical Association's STEPS Forward program offers bite-sized, simple, and affordable solutions to fix office or practice systems of operations.

Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.

As interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.

A slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.

Clinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.

The Painters also answer a question about billing for home health orders during the global period in this "Coding Q&A" column.

Robert A. Dowling, MD, dug into the Centers for Medicare & Medicaid Services’ recently released 2015 data from the "Open Payments" initiative, and summarizes the data on payments made to urologists.

A new meta-analysis links moderate-to-severe lower urinary tract symptoms (LUTS) to heart disease in men, possibly because unhealthy lifestyles boost the risks of both conditions.

"LUTS is an important health care burden, and health care professionals should be screening for its presence in men at risk," writes Steven A. Kaplan, MD.

In this interview, Angela B. Smith, MD, MS, discusses two work force problems in urology, discrepancies in male and female urologist compensation, and solutions for these issues.

A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.

This article provides an update on the risk factors for stone disease and its presentation in children, and offers practical tips on its evaluation, treatment, and prevention.

The literature is rife with information and data, sometimes conflicting, as to whether disclosure and defensive medicine are beneficial to reducing liability and the chances of a lawsuit. One reason for this conflicting data is that the health care system as a whole is in the midst of a massive change, going from an authoritative physician model to one in which patients are increasingly engaged in their own medical care and treatment decisions.

"The marriage process, regardless of age, requires careful thought about a number of financial situations a couple will likely face," write Joel M. Blau, CFP, and Ronald J. Paprocki, JD, CFP, CHBC.

The AUA and other organizations have been urging Congress to create transparency and accountability within the USPSTF while adding input and feedback from patients and specialists involved in treating the conditions for which it is developing recommendations.

In this blog post, urology resident Nirmish Singla, MD, discusses the hidden gains that quality improvement initiatives can offer. Read his blog post.

The recent blog post, “The transgender community: Urology has a role and a responsibility,” by Henry Rosevear, MD, prompted comments from several readers. Given the interest in this topic, Urology Times has compiled these comments.

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

A recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.

Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.

Steven Lamm, MD and Darren Sultan, BA look at this and several other misconceptions.

In her latest blog post, Adele M. Caruso, MSN, CRNP, discusses challenges related to bladder cancer surveillance and how they can be overcome.